Source: Fox News
Summary
The U.S. Food and Drug Administration (FDA) has approved the first non-antipsychotic drug treatment for agitation in Alzheimer’s disease patients. The drug, Auvelity, was originally approved in 2022 for treating adults with major depressive disorder. Two randomized trials found Auvelity to be efficacious in treating agitation in Alzheimer’s disease. The drug is administered in rapid-onset extended-release tablets and has common side effects such as dizziness, upset stomach, and headache.
Our Reading
The advice sounds familiar. The FDA’s approval of Auvelity for agitation in Alzheimer’s disease patients represents a significant advancement in treatment options. However, it’s worth noting that the drug’s prescribing information warns of increased suicidal thoughts in younger adults and the risk of seizures, elevated blood pressure, and mania in susceptible patients. The treatment’s efficacy and safety will likely be closely monitored as it becomes more widely used.
This approval enters another phase in the ongoing search for effective treatments for Alzheimer’s disease. As the FDA commissioner noted, Auvelity provides an additional important treatment for complications of this devastating disease. However, it’s also important to recognize that the treatment landscape for Alzheimer’s is constantly evolving, and what may be considered a breakthrough today may be reevaluated in the future.
The approval of Auvelity highlights the complexities of treating Alzheimer’s disease and the need for continued research and development of new treatments. As Dr. Marc Siegel noted, Auvelity is a good choice over anti-psychotics in many cases, but it’s not without its own set of risks and side effects. Ultimately, the treatment of Alzheimer’s disease will likely involve a multifaceted approach that takes into account the unique needs and circumstances of each patient.
Author: Evan Null
